Last updated: May 26, 2026
Clarithromycin Suppliers: Who Manufactures Clarithromycin API, Intermediates, and Finished Dosage Forms
Clarithromycin supply chains split into (1) active pharmaceutical ingredient (API) and key intermediates, and (2) finished dose manufacturers that fill clarithromycin into tablets, extended-release tablets, and oral liquids for the US and global markets. The supplier set varies by dosage form and strength, and many branded and generic products source from multiple API vendors.
What companies supply clarithromycin API and where are they located?
Clarification of “suppliers” depends on whether you mean API producers, intermediate makers, or finished-dose manufacturers. In clarithromycin, the most decision-relevant supplier categories for R&D, licensing, procurement, and litigation are:
API suppliers
- Market participants that produce clarithromycin API for generic and branded supply.
- Contract manufacturers that synthesize clarithromycin and package API for distributors and finished-dose makers.
- Specialized intermediate producers supplying key steps in macrolide synthesis.
Intermediate suppliers
- Manufacturers producing macrolide core intermediates and ketolide-capable intermediates used in clarithromycin synthesis routes.
Finished-dose manufacturers
- Tablet, extended-release (ER) tablet, and oral suspension manufacturers.
- Often company names differ by geography and regulatory filing ownership even when the API origin is shared.
Which clarithromycin dosage forms have the most supplier concentration risk?
Supplier risk concentrates by dosage form because regulatory filings, bioequivalence standards, and manufacturing controls differ.
Immediate-release tablets (clarithromycin IR)
- More common in generic supply.
- Higher potential for multiple parallel sourcing of API, with additional variability in tableting excipients and dissolution targets.
Extended-release tablets (clarithromycin ER)
- Fewer qualified formulations globally.
- Supply disruptions can be amplified because ER requires distinct formulation and process controls.
Oral suspension
- Sensitive to formulation stability, viscosity control, and packaging.
- Often sourced from a narrower set of qualified finished-dose manufacturers, especially for pediatric markets.
What are typical clarithromycin API sourcing models used by generics?
Generic manufacturers commonly use one of three procurement models:
-
Direct API purchase from API manufacturers
- Finished-dose manufacturer holds the regulatory filing and sources clarithromycin API from one or more approved suppliers.
-
Long-term supply agreements with API and packagers
- API and packaging are contracted to reduce incoming quality variation.
-
Platform purchasing through brokers and distributors
- Used when product scope is broad, but increases incoming quality and chain-of-custody diligence requirements.
How do you evaluate clarithromycin supplier quality and regulatory fit (US FDA context)?
Supplier evaluation for US submissions usually maps to these checkpoints:
Drug Substance (API)
- Identity, potency, impurity profile, and residual solvent controls consistent with the approved specification.
- Evidence of GMP manufacturing and validated cleaning and segregation controls.
- Supply chain traceability and change control, including site, process, and specification changes.
Drug Product (tableting/ER encapsulation/suspension)
- Dissolution targets aligned with the formulation’s reference product.
- Process capability for mixing, granulation, tablet compression, and ER release mechanism control.
- Stability data at intended storage conditions including aqueous and humidity exposure controls for suspension.
Quality agreements
- Clear allocation of responsibilities on testing, method transfer, batch release, and deviation handling.
- Audit rights and regulatory inspection readiness.
What patent and exclusivity issues can constrain clarithromycin sourcing?
Clarithromycin itself is an older small-molecule antibiotic. Today, supplier constraints usually come from regulatory and quality qualification rather than active drug exclusivity, but filings can still be shaped by:
Oral formulation and ER formulation patents
- Even after primary compound patents expire, formulation and process patents can persist, depending on jurisdiction and claim coverage.
Analytical method and impurity control patents
- Spec-driven manufacturing may be influenced by patent-covered impurity profiles and analytical methods.
Generic entry packaging and process lock-in
- Certain suppliers become “locked-in” due to established regulatory comparability packages and repeat bioequivalence acceptance.
How many clarithromycin suppliers are active in the US market?
US supplier counts depend on the current portfolio on the Orange Book and the active ANDA AND marketplace distribution. A complete supplier census requires reconciling:
- ANDA applicant information,
- drug product manufacturers and repackagers,
- ANDA drug substance data (when available),
- API manufacturer disclosures (if included in filings or known supply disclosures).
A procurement strategy that assumes a single supplier for API or ER formulation can be exposed to manufacturing disruptions, batch failures, or inspection outcomes. Diversifying across at least two upstream sources is a common risk mitigation approach in generics supply chains.
Which clarithromycin suppliers are used for branded products versus generics?
Branded products typically rely on a narrower upstream base tied to validated commercial manufacturing sites. Generics typically broaden sourcing, with:
- multiple API upstream sources,
- multiple finished-dose sites,
- alternating manufacturing plants between strength and NDC sets.
This impacts contract strategy because the same applicant may use different manufacturers over time, depending on capacity and quality performance.
What supplier documentation matters for clarithromycin procurement and audits?
For an operational procurement file, the most commonly requested documents include:
API
- GMP certificate and recent quality metrics (deviations, OOS, batch failures).
- Certificates of analysis for multiple recent batches.
- Specification sheet, CoA trend summaries, and impurity method summaries.
- Change control notifications and vendor qualification package.
Drug product
- CoA, dissolution profiles by lot, and stability reports.
- Packaging and labeling compliance evidence.
- Validation documentation for manufacturing process changes.
Chain-of-custody
- Temperature and handling logs where applicable.
- Batch genealogy and traceability.
What geographic supplier risks exist for clarithromycin?
Supply concentration can shift by:
- regional API manufacturing capacity,
- regulatory inspection outcomes affecting release approvals,
- export logistics affecting lead times,
- regional excipient availability for suspensions and ER systems.
For clarithromycin, supply risk is usually driven by upstream API availability and batch release reliability rather than formulation complexity alone.
How does clarithromycin supply compare with other macrolide antibiotics (azithromycin, erythromycin)?
Compared with azithromycin and erythromycin, clarithromycin is:
- less frequently tied to the same single-vendor capacity bottleneck than erythromycin historically has seen in some periods,
- but ER formulations and specific impurity control requirements can create localized qualification barriers.
Market dynamics often show azithromycin having broader API availability due to higher demand, while clarithromycin demand supports fewer plants per region.
What generic entry risks exist for clarithromycin ER and suspension?
Generic entry risk is typically driven by:
- dissolution sensitivity in ER systems,
- excipient and processing constraints for suspension stability,
- impurity profile alignment with reference-listed specifications.
Even with expired clarithromycin compound exclusivity, formulation-specific approvals can face:
- slower tech transfer cycles,
- additional stability and dissolution comparability tests,
- tighter batch release and impurity monitoring.
Key Takeaways
- Clarithromycin supply is segmented into API/intermediate producers and finished-dose manufacturers, with supplier counts varying by dosage form.
- The highest supplier qualification and disruption risk is typically in ER tablets and oral suspension due to formulation-specific controls.
- Procurement and audit readiness depend on incoming API quality evidence, finished-dose dissolution/stability performance, and robust quality agreements.
- Supplier diversification is a practical mitigation because upstream capacity, batch release reliability, and inspection outcomes drive real-world lead-time and availability.
FAQs
1) What documentation should a clarithromycin API supplier provide for GMP qualification?
GMP evidence, CoAs for multiple recent lots, API specifications including impurity profile, change control history, and batch traceability.
2) How do clarithromycin ER suppliers qualify dissolution performance?
By aligning the formulation and process to validated dissolution targets, supported by stability and comparative dissolution testing across the proposed commercial scale.
3) What typically causes clarithromycin manufacturing batch failures?
Quality deviations tied to impurity control, moisture sensitivity in intermediates or formulations, or dissolution nonconformance linked to granulation and compression variability.
4) Can a finished-dose manufacturer use multiple clarithromycin API suppliers?
Yes, but only with vendor qualification and comparability evidence to support consistent impurity and performance attributes under the regulatory filing’s quality system.
5) What is the main supply-chain mitigation strategy for clarithromycin?
Dual-sourcing API and maintaining pre-qualified secondary finished-dose manufacturing capacity for ER and suspension.
References
- US FDA, Drugs@FDA (clarithromycin product listings and regulatory status). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA Orange Book (approved drug products with therapeutic equivalence evaluations). https://www.accessdata.fda.gov/scripts/cder/ob/
